Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is a promising biopharmaceutical company with strong financials and multiple promising drug candidates in their pipeline. Their recent FDA approvals and plans for label expansion and a new delivery method show potential for continued growth in the future. However, there is always a risk in drug development and competition in the market could impact their success.

Bears say

argenx is heavily reliant on one product, Vyvgart, for a majority of its revenue, making it vulnerable to potential competition or failure to demonstrate sustained efficacy in clinical trials. Their heavy investment in pipeline development may not pay off in the long run as the potential market for their treatments is small and niche. Additionally, potential pricing pressures in the biopharmaceutical industry could impact their profitability in the future.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,079.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,079.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.